Oscotec Inc.
KOSDAQ 039200.KQ
Oscotec Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -35.88
-
Oscotec Inc. 52-week high Price to Earnings Ratio (P/E) is -28.73 on February 06, 2024, which is 19.92% above the current Price to Earnings Ratio (P/E).
-
Oscotec Inc. 52-week low Price to Earnings Ratio (P/E) is -65.12 on July 15, 2024, which is -81.51% below the current Price to Earnings Ratio (P/E).
-
Oscotec Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -45.67.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Sung-Hee Son |
| IPO Date | Jan. 17, 2007 |
| Location | South Korea |
| Headquarters | A Building, Korea Bio Park |
| Employees | 50 |
| Sector | Health Care |
| Industries | |
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
Past 5 years
USD 89.21
USD 108.37
USD 3.70
StockViz Staff
January 15, 2025
Any question? Send us an email